Ascendiant Capital Rates Synergy CHC (SNYR) buy
Ascendiant Capital reaffirms its buy rating for Synergy CHC Corp., setting a target price of $3.75 as the stock trades around $0.20, a 1813.27% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Ascendiant Capital rated Synergy CHC Corp. ($SNYR) "buy" with a $3.75 price target on June 10, 2026.
SNYR
Synergy CHC Corp.
Key Points
- Ascendiant Capital reiterated its buy rating on Synergy CHC Corp. (SNYR) on June 10, 2026, with a target price of $3.75.
- The stock currently trades at about $0.20, a significant discount from its target, suggesting potential upside.
- Synergy CHC Corp. operates in the healthcare sector, providing various consumer health and lifestyle products.
Get $SNYR trade alerts by text
We text you when insiders, Congress or big funds trade $SNYR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Synergy CHC Corp. alert may contain errors. Disclosures
Ascendiant Capital Reiterates Buy Rating
On June 10, 2026, Ascendiant Capital reiterated its buy rating on Synergy CHC Corp. (SNYR) with a target price of $3.75. The stock is currently trading at around $0.20, which indicates a considerable upside potential compared to the set target.
Recent Changes in Analyst Ratings
This reiteration from Ascendiant comes as no surprise, considering the firm has been bullish on Synergy CHC in its recent assessments. The previous rating was made on the same day, emphasizing a consistent outlook from the analyst Edward Woo.
Stock Price Context
The current trading price of $0.20 is significantly lower than the target price of $3.75. This presents an interesting opportunity for investors, as the stock trades well below its 52-week high of $2.96, suggesting that it may be undervalued at present.
$SNYR price target
Synergy CHC Corp. daily closes and this analyst's $3.75 target. Not advice.
What SNYR Does
Synergy CHC Corp. is based in Windham, Maine, and specializes in consumer healthcare and lifestyle products. The company offers a range of items, including nutritional supplements, wellness products, and over-the-counter drugs, catering to markets across the United States and internationally.
Next Steps
Investors will be watching for Synergy CHC's upcoming earnings report scheduled for August 14, 2026. With Ascendiant Capital's positive outlook, the report could provide further insights into the company’s ability to recover from its recent revenue decline.
Related Filing Alerts
Source: Ascendiant Capital's rating change on $SNYR (Jun 10, 2026). Written by software, not financial advice. How we make alerts